NCT04396886

Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Phase II Prospective Study of Bintrafusp Alfa in Previously Treated Patients With Recurrent and Metastatic (R/M) Non-keratinizing Nasopharyngeal Carcinoma (NPC)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: The University of Hong Kong · Academic / Other
• Sex: All
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

This would be a phase II prospective single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of bintrafusp alfa in previously treated patients with recurrent and metastatic (R/M) non-keratinizing nasopharyngeal carcinoma (NPC).

Detailed description

All the patients must be registered with the Investigator(s) prior to initiation of treatment. The registration desk will confirm all eligibility criteria and obtain essential information (including patient number). Patients shall receive Bintrafusp alfa treatment through intravenous therapy every two weeks up until disease progression, unacceptable toxicity or for a maximum of 2 years. Survival Follow-up till 2 years will also be performed.

Conditions

• Nasopharyngeal Carcinoma
• Recurrent Carcinoma
• Metastatic Cancer
• Non-keratinizing Carinoma

Interventions

Type	Name	Description
DRUG	Bintrafusp Alfa	Bintrafusp alfa will be administered intravenously every 2 weeks

Timeline

• Start date: 2020-02-27
• Primary completion: 2022-09-30
• Completion: 2023-07-26
• First posted: 2020-05-21
• Last updated: 2024-05-09

Locations

1 site across 1 country: Hong Kong